Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

This study has been completed.
Information provided by (Responsible Party):
David Kaminsky, MD, University of Vermont Identifier:
First received: July 2, 2008
Last updated: October 27, 2016
Last verified: October 2016
This research is being conducted to help us better understand what causes exercise induced asthma. The investigators hypothesize that two types of chemicals, cysteinyl leukotrienes and adenosine, play an important role. The investigators will be measuring these chemicals in the exhaled breath of volunteers with exercise induced asthma as they undergo a test to mimic exercise induced asthma. The investigators will determine how the levels of these chemicals change in association with how lung function changes before, during and after an episode of exercise induced asthma.

Condition Intervention
Asthma, Exercise Induced
Procedure: Hyperpnea challenge

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm Determined by Dynamic Analysis of Exhaled Breath Condensate.

Resource links provided by NLM:

Further study details as provided by David Kaminsky, MD, University of Vermont:

Primary Outcome Measures:
  • Change in level of cystLTs and adenosine [ Time Frame: Before and after hyperpnea challenge ]

Secondary Outcome Measures:
  • Change in pH of EBC and change in pulmonary function [ Time Frame: Before and after hyperpnea challenge ]

Enrollment: 8
Study Start Date: October 2007
Study Completion Date: July 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Asthmatics with exercise induced bronchospasm
Procedure: Hyperpnea challenge
5 minutes of dry air hyperpnea to induce bronchospasm


Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Asthmatics with exercise induced bronchospasm

Inclusion Criteria:

  • Physician diagnosed asthma
  • Age 12-75 yrs
  • FEV1 > 70% predicted
  • HIB response > 10 %
  • No smoking last 6 mo and < 10 pack yrs
  • No URI last 4 weeks
  • No asthma exacerbation last 4 weks
  • Able to withhold SABA > 8 hrs and LABA > 24 hrs

Exclusion Criteria:

  • Other lung disease
  • Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00710255

United States, Vermont
Vermont Lung Center
Colchester, Vermont, United States, 05446
Sponsors and Collaborators
University of Vermont
Principal Investigator: David A. Kaminsky, MD University of Vermont
  More Information

Responsible Party: David Kaminsky, MD, Professor, University of Vermont Identifier: NCT00710255     History of Changes
Other Study ID Numbers: CHRMS 08-023
Merck IISP 32710
Study First Received: July 2, 2008
Last Updated: October 27, 2016

Keywords provided by David Kaminsky, MD, University of Vermont:
Exercise induced bronchospasm
Hyperpnea induced bronchospasm
exhaled breath condensate

Additional relevant MeSH terms:
Bronchial Spasm
Asthma, Exercise-Induced
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017